BioCardia’s Upcoming Conference Call
BioCardia, Inc. (NASDAQ: BCDA), a leader in cellular therapies for treating cardiovascular and pulmonary diseases, will host a corporate update and financial results conference call. Scheduled for November 12, 2025, at 4:30 PM EDT, the call is significant for shareholders and interested parties.
Details of the Conference Call
During the call, BioCardia will share insights on performance metrics for the three and nine months ending on September 30, 2025. After the management’s updates, there will be an interactive question-and-answer session, allowing participants to engage directly with the executive team.
How to Participate
Participants planning to listen to the conference call are encouraged to register beforehand. A registration link is available for those who want to receive a dial-in number directly. For those unable to register, they can join by calling 1-833-316-0559 within the U.S. or +1-412-317-5730 for international access. All guests are requested to log in approximately ten minutes before the scheduled start.
Webcast Availability
For individuals who prefer to attend virtually, the conference call will also be available via live webcast. This provides an accessible option for listening and following the updates shared during the session.
Replay Information
Those unable to attend the call can still catch up on valuable information. A replay of the conference will be accessible about an hour after its conclusion, lasting until late November, ensuring extended access to the discussed content.
About BioCardia, Inc.
Established in Sunnyvale, California, BioCardia is pioneering the field of cell and cell-derived therapies, aiming to provide innovative solutions for complex cardiovascular and pulmonary conditions. Their key offerings include CardiAMP® and CardiALLO™ therapies, fundamental components of their biotherapeutic platforms that are currently undergoing vital clinical trials.
Innovations in Therapeutics
BioCardia’s approach to therapy centers around cutting-edge technologies, including the Helix™ biotherapeutic delivery system and the Morph® vascular navigation platform. These innovations underline the company’s commitment to delivering effective and targeted treatments, fostering advancements in healthcare.
Investor Relations Contacts
Inquiries from investors can be directed to Miranda Peto, available at (650) 226-0120 or via email. For detailed financial information or questions about the company's operations, David McClung, the Chief Financial Officer, is also accessible at the same phone number.
Frequently Asked Questions
1. When is the BioCardia conference call scheduled?
The conference call is set for November 12, 2025, at 4:30 PM EDT.
2. How can I participate in the conference call?
Participants can register through the provided registration link or call the specified numbers to join.
3. Will the conference call be recorded?
Yes, a replay will be available approximately one hour after the call, lasting until November 26, 2025.
4. What topics will be covered in the call?
The call will cover corporate updates and financial results for the third quarter of 2025.
5. How can I contact BioCardia for investor relations?
For investor inquiries, reach out to Miranda Peto at (650) 226-0120.
